Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “outperform” rating reiterated by RBC Capital Markets in a report issued on Tuesday. They presently have a $648.00 price objective on the biopharmaceutical company’s stock. RBC Capital Markets’ price target would suggest a potential upside of 63.14% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the company. Robert W. Baird reissued a “neutral” rating and set a $448.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Zacks Investment Research cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Swann set a $530.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday. Canaccord Genuity reissued a “hold” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. Finally, Chardan Capital reissued a “sell” rating and set a $325.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $480.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.40% on Tuesday, hitting $397.20. The stock had a trading volume of 557,441 shares. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59. The firm’s 50-day moving average is $404.40 and its 200-day moving average is $391.48. The company has a market cap of $41.56 billion, a P/E ratio of 61.97 and a beta of 1.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.17. The company earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.89 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals will post $11.00 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the transaction, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.40% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares during the last quarter. Capital World Investors boosted its position in Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock valued at $2,558,678,000 after buying an additional 312,008 shares during the last quarter. Wellington Management Group LLP boosted its position in Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock valued at $2,239,195,000 after buying an additional 1,426,801 shares during the last quarter. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock valued at $1,669,035,000 after buying an additional 92,467 shares during the last quarter. Finally, State Street Corp boosted its position in Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock valued at $1,080,272,000 after buying an additional 15,272 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.